AR094887A1 - Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina - Google Patents
Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepinaInfo
- Publication number
- AR094887A1 AR094887A1 ARP140100595A ARP140100595A AR094887A1 AR 094887 A1 AR094887 A1 AR 094887A1 AR P140100595 A ARP140100595 A AR P140100595A AR P140100595 A ARP140100595 A AR P140100595A AR 094887 A1 AR094887 A1 AR 094887A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- optionally substituted
- fluorine
- fluorine atoms
- Prior art date
Links
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical class C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 title 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 12
- 229910052731 fluorine Inorganic materials 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Reivindicación 1: Un compuesto representado por la formula (1) o una sal de adición ácida farmacéuticamente aceptable de este, caracterizado porque R es un átomo de hidrógeno o grupo alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 átomos de flúor; donde cuando R es un átomo de hidrogeno, R¹ es un átomo de cloro, un átomo de bromo, un grupo trifluorometilo, un grupo etilo, un grupo trifluorometoxi, un grupo metoxi sustituido con un grupo fenilo, un grupo metoxi sustituido con un grupo cicloalquilo C₃₋₈, un grupo etoxi sustituido opcionalmente con 1 a 3 átomos de flúor, o un grupo cicloalquil C₃₋₈oxi, R² es un átomo de flúor, un átomo de cloro, un grupo metilo sustituido opcionalmente con 2 a 3 átomos de flúor, un grupo metoxi sustituido opcionalmente con 1 a 3 átomos de flúor, o un grupo etoxi sustituido opcionalmente con 1 a 3 átomos de flúor, R³ es un átomo de hidrógeno o un grupo metilo, y R⁴ es un átomo de flúor o un grupo metilo sustituido opcionalmente con 1 a 3 átomos de flúor; o donde R es un grupo alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 átomos de flúor, R¹ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 átomos cha flúor, un grupo alcoxi C₁₋₆ sustituido opcionalmente con 1 a 3 sustituyentes seleccionados de un átomo de flúor y un grupo cicloalquilo C₃₋₈, un grupo cicloalquil C₃₋₈oxi, o un grupo heterocicloalquiloxi de 4 a 6 miembros, R² es un átomo de hidrógeno, un grupo ciano, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 sustituyentes seleccionados de un átomo de flúor y un grupo hidroxilo, o un grupo alcoxi C₁₋₆ sustituido opcionalmente con 1 a 3 sustituyentes seleccionados de un átomo de flúor, un grupo cicloalquilo C₃₋₈ y un grupo heterocicloalquilo de 4 a 6 miembros, R³ es un átomo de hidrógeno o un grupo alquilo C₁₋₆, y R⁴ es un grupo alquilo C₁₋₆ sustituido opcionalmente con 1 a 3 sustituyentes seleccionados de un átomo de flúor y un grupo hidroxilo, o un grupo alcoxi C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770469P | 2013-02-28 | 2013-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094887A1 true AR094887A1 (es) | 2015-09-02 |
Family
ID=51388759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100595A AR094887A1 (es) | 2013-02-28 | 2014-02-26 | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9458176B2 (es) |
| EP (1) | EP2963043B1 (es) |
| JP (1) | JP5654715B1 (es) |
| KR (1) | KR102190597B1 (es) |
| CN (1) | CN105008375B (es) |
| AR (1) | AR094887A1 (es) |
| AU (1) | AU2014221775B2 (es) |
| BR (1) | BR112015020545A2 (es) |
| CA (1) | CA2901168C (es) |
| CL (1) | CL2015002391A1 (es) |
| CY (1) | CY1121231T1 (es) |
| DK (1) | DK2963043T3 (es) |
| ES (1) | ES2685025T3 (es) |
| HK (1) | HK1217697A1 (es) |
| HR (1) | HRP20181349T1 (es) |
| HU (1) | HUE040219T2 (es) |
| IL (1) | IL240402A (es) |
| LT (1) | LT2963043T (es) |
| MX (1) | MX362920B (es) |
| PE (1) | PE20151651A1 (es) |
| PH (1) | PH12015501878A1 (es) |
| PL (1) | PL2963043T3 (es) |
| PT (1) | PT2963043T (es) |
| RS (1) | RS57602B1 (es) |
| RU (1) | RU2659219C2 (es) |
| SG (1) | SG11201505252VA (es) |
| SI (1) | SI2963043T1 (es) |
| TW (1) | TWI622592B (es) |
| UA (1) | UA114950C2 (es) |
| WO (1) | WO2014133022A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| TWI622578B (zh) | 2011-12-21 | 2018-05-01 | 諾維拉治療公司 | Ｂ型肝炎抗病毒劑 |
| BR112015004192B1 (pt) | 2012-08-28 | 2021-02-09 | Janssen Sciences Ireland Uc | sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| BR112015025052A2 (pt) | 2013-04-03 | 2021-07-06 | Janssen Sciences Ireland Uc | derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b |
| MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| EA035500B1 (ru) | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| EP3357906B1 (en) | 2013-07-25 | 2019-12-04 | Janssen Sciences Ireland Unlimited Company | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| WO2015120178A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| CN105980378B (zh) | 2014-02-06 | 2019-09-27 | 爱尔兰詹森科学公司 | 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| JP2017206438A (ja) * | 2014-08-22 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ） |
| WO2016033190A1 (en) * | 2014-08-27 | 2016-03-03 | Eisai, Inc. | Radiotracer compounds |
| HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
| CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CN107847762A (zh) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法 |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| TW201837036A (zh) | 2017-01-10 | 2018-10-16 | 德商拜耳廠股份有限公司 | 作為除害劑之雜環衍生物（一） |
| EP3568395A1 (de) | 2017-01-10 | 2019-11-20 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| JP2021035911A (ja) * | 2017-11-15 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体及びその医薬用途 |
| JP7242548B2 (ja) | 2017-11-24 | 2023-03-20 | 住友ファーマ株式会社 | ６，７－ジヒドロピラゾロ［１，５－ａ］ピラジノン誘導体及びその医薬用途 |
| AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| US11155547B1 (en) * | 2020-06-18 | 2021-10-26 | Alterity Therapeutics Limited | Compounds for and methods of treating diseases |
| CN116033828A (zh) | 2020-07-02 | 2023-04-28 | 拜耳公司 | 作为害虫防治剂的杂环衍生物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268626C (zh) * | 2001-04-12 | 2006-08-09 | 弗·哈夫曼-拉罗切有限公司 | 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物 |
| RU2412943C2 (ru) | 2005-03-23 | 2011-02-27 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2 |
| ATE463495T1 (de) * | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| CA2657835C (en) | 2008-03-07 | 2017-09-19 | Mathieu Audet | Documents discrimination system and method thereof |
| AU2009319387B2 (en) * | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| WO2010068520A2 (en) * | 2008-12-11 | 2010-06-17 | Cara Therapeutics, Inc. | Substituted imidazoheterocycle derivatives |
| JP2012513399A (ja) * | 2008-12-22 | 2012-06-14 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
-
2014
- 2014-02-26 PL PL14756740T patent/PL2963043T3/pl unknown
- 2014-02-26 CA CA2901168A patent/CA2901168C/en active Active
- 2014-02-26 RS RS20180992A patent/RS57602B1/sr unknown
- 2014-02-26 EP EP14756740.8A patent/EP2963043B1/en active Active
- 2014-02-26 BR BR112015020545A patent/BR112015020545A2/pt active Search and Examination
- 2014-02-26 LT LTEP14756740.8T patent/LT2963043T/lt unknown
- 2014-02-26 DK DK14756740.8T patent/DK2963043T3/en active
- 2014-02-26 AU AU2014221775A patent/AU2014221775B2/en not_active Ceased
- 2014-02-26 AR ARP140100595A patent/AR094887A1/es unknown
- 2014-02-26 WO PCT/JP2014/054724 patent/WO2014133022A1/ja active Application Filing
- 2014-02-26 HU HUE14756740A patent/HUE040219T2/hu unknown
- 2014-02-26 ES ES14756740.8T patent/ES2685025T3/es active Active
- 2014-02-26 UA UAA201508269A patent/UA114950C2/uk unknown
- 2014-02-26 PE PE2015001791A patent/PE20151651A1/es unknown
- 2014-02-26 SG SG11201505252VA patent/SG11201505252VA/en unknown
- 2014-02-26 SI SI201430830T patent/SI2963043T1/sl unknown
- 2014-02-26 US US14/190,356 patent/US9458176B2/en active Active
- 2014-02-26 CN CN201480009750.3A patent/CN105008375B/zh not_active Expired - Fee Related
- 2014-02-26 RU RU2015135967A patent/RU2659219C2/ru active
- 2014-02-26 JP JP2014541469A patent/JP5654715B1/ja active Active
- 2014-02-26 TW TW103106584A patent/TWI622592B/zh not_active IP Right Cessation
- 2014-02-26 KR KR1020157022943A patent/KR102190597B1/ko active IP Right Grant
- 2014-02-26 MX MX2015010741A patent/MX362920B/es active IP Right Grant
- 2014-02-26 PT PT14756740T patent/PT2963043T/pt unknown
-
2015
- 2015-08-06 IL IL240402A patent/IL240402A/en active IP Right Grant
- 2015-08-26 PH PH12015501878A patent/PH12015501878A1/en unknown
- 2015-08-26 CL CL2015002391A patent/CL2015002391A1/es unknown
-
2016
- 2016-05-16 HK HK16105614.7A patent/HK1217697A1/zh not_active IP Right Cessation
-
2018
- 2018-08-23 HR HRP20181349TT patent/HRP20181349T1/hr unknown
- 2018-08-23 CY CY20181100881T patent/CY1121231T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094887A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| AR095011A1 (es) | Compuestos de antranilamida, sus mezclas y usos como plaguicidas | |
| RS54369B1 (en) | NEW QUINOLINE COMPOUNDS SUBSTITUTED AS S-NITROSOGLUTATHION REDUCTASE INHIBITORS | |
| RS53843B1 (en) | BIS (FLUOROALKYL) -1,4-BENZODIAZEPINONE COMPOUNDS | |
| CY1124728T1 (el) | Παραγωγα βενζοξαβορολης για τη θεραπεια βακτηριακων λοιμωξεων | |
| RS54183B1 (en) | PIRAZOLE DERIVATIVES | |
| EA201591429A1 (ru) | 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена | |
| RS52872B (en) | PIRAL UNITS | |
| AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
| RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
| AR095421A1 (es) | Moduladores de p2x7 | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| AR098912A1 (es) | Inhibidores de syk | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| AR095423A1 (es) | 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| EA201591503A1 (ru) | Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| RS52261B (en) | AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR | |
| EA201890098A2 (ru) | Производное хинолона | |
| RU2021109549A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| RS54899B1 (sr) | Jedinjenja tetrahidropirolotiazina | |
| AR098522A1 (es) | Compuesto de triazolo-piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |